Alternative treatment regimens for drug-susceptible tuberculosis — MSF Tuberculosis

What this guideline says

GMJ summary

This section of the MSF Tuberculosis guideline presents two alternative treatment regimens for drug-susceptible tuberculosis (DS-TB) beyond the conventional 6-month course. These regimens are tailored to specific clinical scenarios and patient populations where conventional treatment may not be optimal.

The first alternative is a 4-month rifapentine-based regimen (2HPZ-Mfx/2HP-Mfx) for pulmonary TB and non-severe extrapulmonary TB in adolescents ≥12 years and adults weighing ≥40 kg, with specific eligibility criteria including CD4 count ≥100 for those with HIV infection and absence of fluoroquinolone resistance. The second is a 6-month regimen (6HRZEto) specifically for TB meningitis in children and adolescents under 20 years without HIV infection or inhA mutation, using higher daily doses of standard drugs plus ethionamide instead of ethambutol for better central nervous system penetration.

Both alternative regimens require specific drug supplies (rifapentine or ethionamide) and lack fixed-dose combinations, which may complicate adherence. Implementation of the rifapentine regimen also requires drug susceptibility testing for fluoroquinolones. The ethionamide regimen for TB meningitis has shown lower mortality but more neurological sequelae compared to the conventional 12-month regimen, though no clinical trials have directly compared the two approaches.

Key points

For clinicians — doses and thresholds as stated in the guideline

1. 4-month rifapentine regimen (2HPZ-Mfx/2HP-Mfx) is an alternative for pulmonary TB and non-severe extrapulmonary TB in adolescents ≥12 years and adults
2. Eligibility for 4-month regimen requires: weight ≥40 kg, CD4 ≥100 if HIV-infected, and no fluoroquinolone resistance
3. 6-month ethionamide regimen (6HRZEto) is for TB meningitis in children and adolescents under 20 years without HIV or inhA mutation
4. Higher daily doses for 6HRZEto regimen: isoniazid 20 mg/kg (max 400 mg), rifampicin 20 mg/kg (max 600 mg), pyrazinamide 40 mg/kg (max 2 g), ethionamide 20 mg/kg (max 750 mg)
5. Both alternative regimens lack fixed-dose combinations, making adherence more challenging
6. Rifapentine regimen requires drug susceptibility testing for fluoroquinolones before use
7. Ethionamide regimen offers better central nervous system penetration than ethambutol for TB meningitis
8. The 6HRZEto regimen has shown lower mortality but more neurological sequelae compared to conventional 12-month treatment for TB meningitis

Alternative DS-TB regimens according to the infection site

Table extracted from the guideline

Source: Médecins Sans Frontières, Alternative treatment regimens for drug-susceptible tuberculosis — MSF Tuberculosis. Reproduced in summary form.

From the guideline

Verbatim

“Small studies have shown lower mortality, but more neurological sequelae with the 6HRZEto regimen compared to the 12-month conventional regimen.”

Editor’s perspective

Why this matters for Georgia and the region

Applicability

Georgia and the South Caucasus

Questions this guideline answers

Quick answers

Related on GMJ

Interconnected resources

GMJ Guidelines Library records are original summaries written by the GMJ editorial team from the issuer’s published document and reviewed by a physician. They do not replace the full guideline. The document is the copyright of its issuer and is linked, not hosted. Spotted an error or a newer edition? Tell the Guidelines Desk.